细胞因子IL-36γ提升CAR-T细胞功能并诱导内源性抗肿瘤反应
研究显示,分泌白细胞介素-36γ(IL-36γ)的CAR-T细胞较传统CAR-T细胞显著改善扩增与持久性,并实现更优的肿瘤清除。IL-36γ通过自分泌方式增强细胞功能,同时激活内源性抗原呈递细胞(APC)和T细胞,形成继发性抗肿瘤反应,延迟抗原阴性肿瘤攻击的进展。
要点
- 分泌IL-36γ的CAR-T细胞扩增和持久性显著改善,肿瘤清除优于传统CAR-T细胞。
- IL-36γ通过自分泌方式增强CAR-T细胞功能。
- IL-36γ激活内源性APC和T细胞,形成继发性抗肿瘤反应,延迟抗原阴性肿瘤进展。
核心结论
- 分泌IL-36γ的CAR-T细胞较传统CAR-T细胞显著改善扩增和持久性,并实现更优的肿瘤清除。
- IL-36γ通过自分泌方式增强CAR-T细胞功能,并激活内源性APC和T细胞形成继发性抗肿瘤反应,延迟抗原阴性肿瘤攻击的进展。
- 数据提供临床前证据支持该设计转化以改善CAR-T细胞介导的抗肿瘤反应。
研究设计与样本
- 临床前研究,比较分泌IL-36γ的CAR-T细胞与传统CAR-T细胞的功能和抗肿瘤效果。
主要发现
- 分泌IL-36γ的CAR-T细胞较传统CAR-T细胞显著改善扩增和持久性,并实现更优的肿瘤清除。
- IL-36γ通过自分泌方式增强CAR-T细胞功能。
- IL-36γ激活内源性APC和T细胞,形成继发性抗肿瘤反应,延迟抗原阴性肿瘤攻击的进展。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable responses in B-cell malignancies. However, many patients suffer from limited response and tumor relapse due to lack of persisting CAR T cells and immune escape. These clinical challenges have compromised the long-term efficacy of CAR T-cell therapy and call for the development of novel CAR designs. We demonstrated that CAR T cells secreting a cytokine interleukin-36γ (IL-36γ) showed significantly improved CAR T-cell expansion and persistence, and resulted in superior tumor eradication compared with conventional CAR T cells. The enhanced cellular function by IL-36γ was mediated through an autocrine manner. In addition, activation of endogenous antigen-presenting cells (APCs) and T cells by IL-36γ aided the formation of a secondary antitumor response, which delayed the progression of antigen-negative tumor challenge. Together, our data provide preclinical evidence to support the translation of this design for an improved CAR T-cell-mediated antitumor response.
引用
- Li X, Daniyan AF, Lopez AV, et al. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response. Leukemia. 2020. PMID: 32447345. doi:10.1038/s41375-020-0874-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。